Biopharma

Humana Grows Senior Health Business with Latest Deals

Humana is the second-largest Medicare Advantage payer in the nation after UnitedHealthcare, covering more than four million Medicare Advantage members (DRG July 2019 data). Recently, the insurer has been working to leverage and expand its pharmacy benefit management and care delivery through external investments. Following in the footsteps of competitors like UnitedHealth, Humana is looking […]

Eleven potential blockbuster drugs offer hope, threaten budgets

Crowned by a potential cure for severe hemophilia A, which could become the most expensive drug ever, a new list of 11 medicines expected to generate $1 billion-plus in annual sales by the end of 2024 or earlier throws into stark relief the growing tension between medical innovation and society’s ability to pay for it. […]

First-in-class Tazverik launched for rare sarcoma, wider use will drive market value

Epizyme’s first-in-class EZH2 (enhancer of zeste homolog 2) inhibitor Tazverik (tazemetostat) has become the first therapy to be made available in the U.S. for the treatment of epithelioid sarcoma (ES), a rare soft tissue tumor with a significant unmet need.1,2,3 The drug was granted accelerated approval in January 2020 for the treatment of patients aged […]

Cigna & Oscar Product Could Be New Disruptor in Small Group Market

It’s Oscar season in the health insurance industry. Cigna and Oscar Health kicked off a deal that will add power to each insurer’s position in the commercial space while playing off their respective strengths. Under the name Cigna + Oscar, the two carriers will be offering fully insured plans to small employer groups in to-be-announced […]

Top 10 Predictions for US Managed Markets in 2020 & Beyond

Last year, healthcare insurers laid the groundwork for collaborations that will continue through 2020 as they transition from a focus on geographic expansion, benefit design changes, and organizational up-sizing to vertical alignment and enhanced benefits. Meanwhile, patient outcomes, value-based care, and patient experience will continue to receive a large share of attention, while rising healthcare […]

Top 10 PBM Industry Macrotrends in 2019 & What to Expect in 2020

The PBM industry saw some significant changes in 2019, as some of the largest forces in the market vertically integrated and began implementing disruptive programs that redefined the way pharmacy claims are processed in the U.S. The disruptive strategies spanned from drug acquisition (the way PBMs negotiate discounts with pharma clients) through drug delivery (the […]

Benefits of HTA implementation in the Middle East and North Africa

Health Technology Assessment (HTA) has become one of the most anticipated regulatory advancements across the Middle East and North Africa (MENA) due to its potential to modernize healthcare systems through innovative evaluation of healthcare interventions. Stakeholders see HTA as a tool to optimize healthcare resource allocation through transparent decision making.   The current state of […]

The microbiome mystery: Gaining insights through data mining and analysis

The recent buzz around the microbiome and its effects on human health has both generated and resulted from an exponential growth in research and related publications. In fact, there’s been a 5000% increase in publications in PubMed over the last 15 years – a recent search for “microbiome” returned 62,260 results: 12,971 published to date […]

Express Scripts a Pioneer: Launches Curated List of Digital Therapeutics

What are digital therapeutics? According to the Digital Therapeutics Alliance, digital therapeutics “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health […]

ASH 2019: How Can CAR T-cell Developers Ensure Differentiation in NHL?

Commercial availability of two anti-CD19 CAR T-cell therapies (Kite/Gilead’s Yescarta and Novartis’ Kymriah) has revolutionized treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). To date, the efficacy of these novel therapies has been impressive, but severe side effects, logistical hurdles, and reimbursement delays have hindered delivery of these personalized treatments […]